Two of the vaccines we have for COVID-19 have the distinction of being the first mRNA vaccines to see widespread use in ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...

COVID-19 proved that mRNA vaccines can work. Now, researchers are applying the technology to other diseases. More than half of Americans are fully vaccinated against COVID-19. Many of them received an ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, in partnership with Merck, announced positive results from a five-year ...

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...